MedTrace Logo

Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy

NCT03951012 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2023-10-12

No results posted yet for this study

Summary

Peripheral blood contains enormous quantity of biological information that can improve our patient care. Investigators plan to use proteomics from serum to study its value in predicting the therapeutic response and toxicities of immunotherapy in non-small cell lung cancer (NSCLC).

Conditions

  • Non Small Cell Lung Cancer

Interventions

PROCEDURE

Blood draw

Participants will be approached during their regular clinic visits and asked if an extra tube of blood may be collected prior to the treatment. If consent is not obtained before this visit, a participant will be asked later in the same day. The amount of blood collected will be 2 teaspoons (10mL).

Sponsors & Collaborators

  • Biodesix, Inc.

    collaborator INDUSTRY

  • Muhammad Furqan

    lead OTHER

Principal Investigators

  • Taher Abu Hejleh, MBBS · University of Iowa

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-15
Primary Completion
2022-08-30
Completion
2023-09-08

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03951012 on ClinicalTrials.gov